A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.

Abstract

OBJECTIVES To estimate the anti-tumor activity and toxicity of paclitaxel poliglumex (PPX) in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (EOC) in second or third line treatment. METHOD Twenty-five patients received PPX at 235 mg/m(2) every 21 days (Cohort 1). At a planned analysis following first stage… (More)
DOI: 10.1016/j.ygyno.2008.07.049

Topics

5 Figures and Tables

Cite this paper

@article{Sabbatini2008API, title={A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.}, author={Paul J Sabbatini and Michael W. Sill and David O'Malley and Lisa M Adler and Angeles Alvarez Secord}, journal={Gynecologic oncology}, year={2008}, volume={111 3}, pages={455-60} }